Genocea Biosciences, Inc.
GNCA
GNCA was delisted on the 2nd of June, 2022.
0 hedge funds and large institutions have $0 invested in Genocea Biosciences, Inc. in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $4K → $0 (-$4K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AICPI
ABG Innovation Capital Partners III
Central, Hong Kong,
Hong Kong
|
-$4K |
GNCA Hedge Fund Activity: Q4 2022 in Review
0 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q4 2022, worth a combined $0 — down 100% from $4K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of GNCA and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was ABG Innovation Capital Partners III, exiting entirely with an estimated $4K sold.
- 0 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q4 2022, down from 1 in Q3 2022.
- Funds reported $0 of Genocea Biosciences, Inc. stock for Q4 2022, down 100% quarter-over-quarter.
- 0 funds opened new Genocea Biosciences, Inc. positions in Q4 2022 and 1 closed out, a net change of -1 holder.
- The largest Genocea Biosciences, Inc. seller in Q4 2022 was ABG Innovation Capital Partners III, an estimated $4K sold.
Based on aggregated 13F filings for Q4 2022.